184 related articles for article (PubMed ID: 7857586)
1. Persistent psychosis after reduction in pre- and post-synaptic dopaminergic function.
Wolkin A; Duncan E; Sanfilipo M; Wieland S; Cooper TB; Rotrosen J
J Neural Transm Gen Sect; 1994; 95(1):49-61. PubMed ID: 7857586
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of dopamine synthesis in chronic schizophrenia. Clinical ineffectiveness of metyrosine.
Nasrallah HA; Donnelly EF; Bigelow LB; Rivera-Calimlim L; Rogol A; Potkin S; Rauscher FP; Wyatt RJ
Arch Gen Psychiatry; 1977 Jun; 34(6):649-55. PubMed ID: 17374
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment.
Pickar D; Labarca R; Doran AR; Wolkowitz OM; Roy A; Breier A; Linnoila M; Paul SM
Arch Gen Psychiatry; 1986 Jul; 43(7):669-76. PubMed ID: 3718170
[TBL] [Abstract][Full Text] [Related]
4. Neuroleptics, dopamine, and schizophrenia.
Pickar D
Psychiatr Clin North Am; 1986 Mar; 9(1):35-48. PubMed ID: 2870480
[TBL] [Abstract][Full Text] [Related]
5. Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics.
Duncan E; Wolkin A; Angrist B; Sanfilipo M; Wieland S; Cooper TB; Rotrosen J
Biol Psychiatry; 1993 Oct; 34(8):523-8. PubMed ID: 8274579
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients.
Suzuki E; Kanba S; Nibuya M; Adachi S; Sekiya U; Shintani F; Kinoshita N; Yagi G; Asai M
Biol Psychiatry; 1994 Nov; 36(10):654-61. PubMed ID: 7880934
[TBL] [Abstract][Full Text] [Related]
7. Perspectives on a time-dependent model of neuroleptic action.
Pickar D
Schizophr Bull; 1988; 14(2):255-68. PubMed ID: 2904694
[TBL] [Abstract][Full Text] [Related]
8. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics.
Chouinard G; Jones BD
Am J Psychiatry; 1980 Jan; 137(1):16-21. PubMed ID: 6101522
[TBL] [Abstract][Full Text] [Related]
9. Dopamine in schizophrenia: a review and reconceptualization.
Davis KL; Kahn RS; Ko G; Davidson M
Am J Psychiatry; 1991 Nov; 148(11):1474-86. PubMed ID: 1681750
[TBL] [Abstract][Full Text] [Related]
10. Plasma HVA, neuroleptics, and dopaminergic plasticity.
Dávila R
Biol Psychiatry; 1989 Jan; 25(1):1-3. PubMed ID: 2563229
[No Abstract] [Full Text] [Related]
11. Need for a new framework to understand the mechanism of all antipsychotics.
Stip E; Liddle PF; Soucy JP
J Clin Psychiatry; 2000 May; 61(5):387-8. PubMed ID: 10847316
[No Abstract] [Full Text] [Related]
12. Dopamine, the prefrontal cortex and schizophrenia.
Knable MB; Weinberger DR
J Psychopharmacol; 1997; 11(2):123-31. PubMed ID: 9208376
[TBL] [Abstract][Full Text] [Related]
13. New antipsychotic agents and the future.
Mackay AV
J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):51-3. PubMed ID: 2858482
[TBL] [Abstract][Full Text] [Related]
14. Further studies on the mechanism of antipsychotic action: potentiation by alpha-methyltyrosine of thioridazine effects in chronic schizophrenics.
Carlsson A; Roos BE; Wålinder J; Skott A
J Neural Transm; 1973; 34(2):125-32. PubMed ID: 4146641
[No Abstract] [Full Text] [Related]
15. Plasma homovanillic acid as a predictor of response to neuroleptics.
Davila R; Manero E; Zumarraga M; Andia I; Schweitzer JW; Friedhoff AJ
Arch Gen Psychiatry; 1988 Jun; 45(6):564-7. PubMed ID: 3377643
[TBL] [Abstract][Full Text] [Related]
16. Plasma homovanillic acid in schizophrenics: supportive evidence for the two-subtype hypothesis.
Chen TY; Lee CF; Lung FW; Lee TC; Lin WL; Hu WH; Yeh EK; Chang WH
Taiwan Yi Xue Hui Za Zhi; 1989 Jun; 88(6):584-8. PubMed ID: 2571672
[TBL] [Abstract][Full Text] [Related]
17. Problems in classification of schizophrenics as neuroleptic responders and nonresponders.
Csernansky JG; Kaplan J; Hollister LE
J Nerv Ment Dis; 1985 Jun; 173(6):325-31. PubMed ID: 2860202
[TBL] [Abstract][Full Text] [Related]
18. Neuroleptic-potentiating effect of alpha-methyl-p-tyrosine compared with haloperidol and placebo in a double-blind cross-over trial.
Magelund G; Gerlach J; Casey DE
Acta Psychiatr Scand; 1979 Aug; 60(2):185-9. PubMed ID: 41413
[TBL] [Abstract][Full Text] [Related]
19. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
Davidson M; Kahn RS; Powchik P; Warne P; Losonczy MF; Kaminsky R; Apter S; Jaff S; Davis KL
Arch Gen Psychiatry; 1991 Jan; 48(1):73-6. PubMed ID: 1670618
[TBL] [Abstract][Full Text] [Related]
20. Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis.
Bloemen OJ; de Koning MB; Gleich T; Meijer J; de Haan L; Linszen DH; Booij J; van Amelsvoort TA
Eur Neuropsychopharmacol; 2013 Feb; 23(2):126-32. PubMed ID: 22591910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
